SPRAVATO
Total Payments
$42.4M
Transactions
172,858
Doctors
36,102
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.3M | 46,480 | 16,563 |
| 2023 | $13.8M | 45,720 | 14,760 |
| 2022 | $12.5M | 33,808 | 11,229 |
| 2021 | $3.0M | 14,707 | 5,637 |
| 2020 | $1.5M | 7,378 | 3,200 |
| 2019 | $4.4M | 24,765 | 7,261 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.8M | 1,303 | 46.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.8M | 5,570 | 30.1% |
| Food and Beverage | $4.8M | 156,641 | 11.2% |
| Travel and Lodging | $2.5M | 8,477 | 5.8% |
| Consulting Fee | $2.3M | 809 | 5.5% |
| Royalty or License | $223,848 | 3 | 0.5% |
| Acquisitions | $79,872 | 1 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $4,700 | 5 | 0.0% |
| Education | $2,331 | 49 | 0.0% |
Payments by Type
General
$22.7M
171,555 transactions
Research
$19.8M
1,303 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | Janssen Research & Development, LLC | $14.6M | 0 |
| A Double blind Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Subjects Who Are Assessed to be at Imminent Risk for Suicide | Janssen Research & Development, LLC | $706,656 | 0 |
| Janssen Diagnostics' Leading Edge Initiative Program | Janssen Scientific Affairs, LLC | $704,819 | 0 |
| National Pregnancy Registry for Antidepressants (NPRAD) | Janssen Scientific Affairs, LLC | $609,997 | 0 |
| ESK-871 Time Equivalent Values For Comparative Effective Analysis of Treatments for Major Depression with Suicidal Ideation Phase 1 | Janssen Scientific Affairs, LLC | $215,570 | 0 |
| Assessment of Feasibility of Using Clinician-Directed Cognitive Behavior Therapy Supplemented by a Digital Application in Conjunction With Esketamine (SPRAVATO) in Participants With Treatment-Resistant Depression Feasibility of Using Clinician-Directed and App Supported CBT in Conjunction with SPRAVATO in Participants with TRD | Janssen Research & Development, LLC | $18,300 | 0 |
| An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | Janssen Research & Development, LLC | $14,138 | 0 |
| Assessment of Feasibility of Using Clinician-Directed Cognitive Behavior Therapy Supplemented by a Digital Application in Conjunction With Esketamine (SPRAVATO?) in Participants With Treatment-Resistant Depression Feasibility of Using Clinician-Directed | Janssen Research & Development, LLC | $9,100 | 0 |
Ad
Manufacturing Companies
- Janssen Pharmaceuticals, Inc $21.2M
- Janssen Research & Development, LLC $15.6M
- Janssen Scientific Affairs, LLC $5.5M
- Janssen Global Services, LLC $43,354
- Johnson & Johnson Health Care Systems Inc. $12,729
- Janssen Biotech, Inc. $326.16
- Johnson & Johnson Surgical Vision, Inc. $17.32
Product Information
- Type Drug
- Total Payments $42.4M
- Total Doctors 36,102
- Transactions 172,858
About SPRAVATO
SPRAVATO is a drug associated with $42.4M in payments to 36,102 healthcare providers, recorded across 172,858 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Pharmaceuticals, Inc.
Payment data is available from 2019 to 2024. In 2024, $7.3M was paid across 46,480 transactions to 16,563 doctors.
The most common payment nature for SPRAVATO is "Unspecified" ($19.8M, 46.6% of total).
SPRAVATO is associated with 8 research studies, including "A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression" ($14.6M).